Intuitive Surgical, Inc.

$422.06 ▲ 0.77%
2026-06-06 08:46:00

Explore Intuitive Surgical, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.

Market Cap
$150.56 B
Current Price
$422.06
52W High / Low
$603.88 / $396.68
Stock P/E
50.54
Book Value
$50.19
Dividend Yield
ROCE
15.96%
ROE
16.98%
Face Value
EPS
$8.24
Exp Qtr EPS
Sector
Healthcare

ISRG — Monthly Price History

Adjusted close price  ·  Hover to see price & month

Pros

  • Healthy return on equity.
  • Efficient use of capital employed.
  • Short-term liquidity looks comfortable.
  • Strong operating margin profile.
  • Net margin remains healthy.

Cons

  • Valuation is rich on a P/E basis.

Sift Stocks

S.No. Name Price P.E. Market Cap Div Yld % ROCE ROE 52Week High/ Low Book Value
1. Becton, Dickinson and Company $151.16 36.88 $41.96 B 2.81% 6.35% 4.54% $187.35 / $127.59 $88.96
2. ResMed Inc. $196.04 18.64 $28.33 B 1.24% 23.58% 24.41% $293.81 / $180.26 $40.77
3. Alcon Inc. $66.81 40.34 $26.02 B 0.01% 4.77% 3.71% $74.34 / $47.8 $45.21
4. West Pharmaceutical Services, Inc. $314.5 41.18 $22.35 B 0.33% 17.6% 17.87% $330.88 / $206.8 $44.11
5. Hologic, Inc. $0 31.2 $16.97 B 9.77% 11.01% $76.07 / $61.28 $22.68
6. Solventum Corporation $81.01 9.8 $14.03 B 5.66% 30.71% $88.2 / $62.38 $29.1
7. The Cooper Companies, Inc. $67.34 32.07 $12.87 B 0.02% 6.05% 4.83% $89.83 / $58.89 $42.06

Quarterly Results

Figures shown in M / B

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Sales2.87 B2.51 B2.44 B2.25 B2.41 B
Operating Profit864.3 M759.7 M743.4 M578.1 M734.9 M
Net Profit794.8 M704.4 M658.4 M698.4 M685.7 M
EPS in Rs2.241.981.851.971.93

Profit & Loss

Figures shown in M / B

2025202420232022
Sales10.06 B8.35 B7.12 B6.22 B
Operating Profit2.95 B2.35 B1.77 B1.58 B
Net Profit2.86 B2.32 B1.8 B1.32 B
EPS in Rs8.046.545.063.72

Balance Sheet

Figures shown in M / B

2025202420232022
Total Assets20.46 B18.74 B15.44 B12.97 B
Total Liabilities2.52 B2.21 B2.04 B1.86 B
Equity17.82 B16.43 B13.31 B11.04 B
Current Assets9.78 B7.11 B7.89 B6.25 B
Current Liabilities2.01 B1.75 B1.66 B1.42 B

Cash Flow

Last available yearly cash flow history

2025202420232022
Operating CF3.03 B2.42 B1.81 B1.49 B
Investing CF665.8 M-3.27 B-360.1 M1.37 B
Financing CF-2.36 B150.9 M-287.6 M-2.57 B
Free CF2.49 B1.3 B749.6 M958.4 M
Capex-539.8 M-1.11 B-1.06 B-532.4 M

5Y Margin & Growth History

Last 5 years of annual financial statement data.

2024202320222021
Revenue Growth %17.24%14.49%
Earnings Growth %29.18%35.98%
Profit Margin %27.81%25.24%21.25%
Operating Margin %28.12%24.8%25.35%
Gross Margin %67.46%66.39%67.44%
EBITDA Margin %34.11%31.18%31.23%

Dividend & Split History

Latest dividend payments and stock split events.

Dividend History

No dividend history available.

Stock Splits

DateSplit
2021-10-051:3

Shareholding Pattern

Shares and value shown in M / B

Holder Name Type Shares Value % Out Report Date
Fidelity Concord Street Trust-Fidelity 500 Index Fund Mutual Fund 4.51 M $2.04 B 0.01% 2026-02-28
Invesco QQQ Trust, Series 1 Mutual Fund 7.72 M $3.49 B 0.02% 2026-01-31
iShares Trust-iShares Core S&P 500 ETF Mutual Fund 4.56 M $2.06 B 0.01% 2026-01-31
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust Mutual Fund 4.25 M $1.92 B 0.01% 2026-01-31
SELECT SECTOR SPDR TRT-State Street Health Care Select Sector SPDR ETF Mutual Fund 2.59 M $1.17 B 0.01% 2026-01-31
Vanguard Group Inc Institutional 33.61 M $15.2 B 0.09% 2025-12-31
Blackrock Inc. Institutional 30.52 M $13.8 B 0.09% 2025-12-31
State Street Corporation Institutional 15.7 M $7.1 B 0.04% 2025-12-31
Price (T.Rowe) Associates Inc Institutional 12.55 M $5.68 B 0.04% 2025-12-31
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund Mutual Fund 11.14 M $5.04 B 0.03% 2025-12-31
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund Mutual Fund 8.94 M $4.04 B 0.03% 2025-12-31
Geode Capital Management, LLC Institutional 8.23 M $3.72 B 0.02% 2025-12-31
Capital World Investors Institutional 7.86 M $3.55 B 0.02% 2025-12-31
FMR, LLC Institutional 6.58 M $2.97 B 0.02% 2025-12-31
Morgan Stanley Institutional 5.74 M $2.6 B 0.02% 2025-12-31

Frequently Asked Questions — Intuitive Surgical, Inc.

Will Intuitive Surgical, Inc. stock hit $506 in 2026?

Intuitive Surgical, Inc. (ISRG) is currently trading at $422.06, with a 52-week range of $396.68 to $603.88. Reaching the $506 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.

Wall Street analysts currently have a consensus price target of $599.24 for Intuitive Surgical, Inc., with a Buy rating, and the most bullish analysts see the stock reaching as high as $750.0. Whether Intuitive Surgical, Inc. can reach $506 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Healthcare space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.

Historically, ISRG has delivered a 9.0% CAGR over the past 5 years, which suggests the stock has demonstrated meaningful long-term growth momentum. However, past performance does not guarantee future results, and short-term price movements can be influenced by macroeconomic shifts, interest rate changes, and investor sentiment. Use the ISRG Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.

Is Intuitive Surgical, Inc. stock worth buying at $422.06?

Whether Intuitive Surgical, Inc. (ISRG) is worth buying at $422.06 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:

Valuation: Intuitive Surgical, Inc. trades at a Price-to-Earnings (P/E) ratio of 50.5x, which can be compared against other Healthcare companies to assess whether the stock is expensive or attractively priced relative to its peers.

Profitability & efficiency: Intuitive Surgical, Inc. has a Return on Capital Employed (ROCE) of 16.0%, which indicates the business is generating strong returns on the capital it deploys — a hallmark of a high-quality business. Its Return on Equity (ROE) stands at 17.0%.

Financial health: The Debt-to-Equity ratio of 0.95 indicates a conservative balance sheet with more equity than debt, reducing financial risk.

Analyst view: The Wall Street consensus recommendation for ISRG is currently Buy, with a mean price target of $599.24 based on 30 analyst ratings. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.

What is the analyst price target for Intuitive Surgical, Inc. (ISRG) in 2026?

As of 2026, Wall Street analysts have set a consensus (mean) price target of $599.24 for Intuitive Surgical, Inc. (ISRG), aggregated from 30 analyst ratings. The overall analyst recommendation is Buy.

The price target range spans from $378.0 on the bearish end to $750.0 on the most optimistic projection, with a median target of $615.0. This wide range reflects differing views on Intuitive Surgical, Inc.'s growth prospects, competitive positioning, and macroeconomic sensitivity.

It is important to note that analyst price targets are forward-looking estimates based on financial models, earnings projections, and sector assumptions — they are not guarantees. Targets are regularly revised following quarterly earnings results, management guidance updates, or shifts in the broader economic outlook. Stocks can trade significantly above or below analyst targets depending on market conditions. View the full analyst breakdown and track target revisions on the ISRG analysis page on StockSifting.

Is Intuitive Surgical, Inc. overvalued at a P/E ratio of 50.5x?

Intuitive Surgical, Inc. (ISRG) currently has a Price-to-Earnings (P/E) ratio of 50.5x, meaning investors are paying $50.5 for every $1 of the company's trailing twelve-month earnings. Whether this makes the stock overvalued depends on several contextual factors:

Sector context: The Healthcare sector tends to command higher valuation multiples when growth expectations are elevated. A 50.5x P/E is on the higher end, suggesting the market is pricing in continued strong earnings growth — any disappointment in future earnings could lead to a multiple contraction.

Growth-adjusted valuation: A P/E ratio in isolation can be misleading. Fast-growing companies often deserve higher P/E multiples because their future earnings are expected to rise significantly. A more complete picture comes from looking at the PEG ratio (P/E divided by earnings growth rate) — a PEG below 1 is often considered undervalued, while above 2 may signal overvaluation. Intuitive Surgical, Inc.'s ROCE of 16.0% suggests it has moderate capital returns.

Additional metrics to review: P/E is just one lens. Compare it alongside the Price-to-Book (P/B) ratio, EV/EBITDA, Price-to-Sales, and free cash flow yield for a more complete valuation picture. View all of ISRG's valuation ratios on StockSifting's ratios section. Valuation is subjective and context-dependent — this is not investment advice.

What will Intuitive Surgical, Inc. stock be worth in 2029?

Projecting Intuitive Surgical, Inc. (ISRG)'s stock price 3 years into the future — to 2029 — requires making assumptions about the company's earnings growth, valuation multiple, and broader market conditions. No projection is guaranteed, but historical growth rates offer a reasonable starting point.

Based on ISRG's historical 5-year Compound Annual Growth Rate (CAGR) of 9.0%, if that rate of growth were to continue, the stock could reach approximately $547 by 2029 — up from its current price of $422.06. This projection assumes the historical CAGR holds, which depends on Intuitive Surgical, Inc. sustaining its revenue growth, maintaining profit margins, and the market continuing to reward it at a similar valuation multiple.

In reality, stock prices rarely follow a straight-line trajectory. Short-term volatility, earnings misses, sector rotations, interest rate changes, and macroeconomic events can all cause significant deviations from any modeled path. Investors with a 3-year horizon should focus on the fundamental business trajectory — revenue growth, expanding margins, and free cash flow generation — rather than short-term price fluctuations.

You can model different scenarios — conservative, base, and bull case — using the ISRG Return Calculator on StockSifting. Enter any investment amount and CAGR assumption to see projected outcomes over your chosen time horizon. All projections are mathematical estimates only and do not constitute financial advice.